Skip to main content

Table 2 Clinical effects and adverse events of T cell receptor gene-modified T cell therapies

From: Immune cell therapy for hepatocellular carcinoma

Antigen Type of cancer Type of T cell receptor Effects Adverse events Year of report Reporter [reference]
MART-1 Malignant melanoma Wild type 1/15 PR Fever, fatigue et al. 2006 Duval et al. [81]
MART-1 Malignant melanoma Wild type 2/17 PR Not reported 2006 Morgan et al. [70]
MART-1 Malignant melanoma High affinity 66/20 PR Disorders of the skin, eye, and inner ear 2009 Johnson et al. [71]
MART-1 Malignant melanoma High-affinity modification 9/13 tumor regression Respiratory failure 2014 Chodon et al. [82]
gp100 Malignant melanoma Mouse origin 1/16 CR, 2/16 PR Not reported 2010 Davis et al. [83]
p53 Breast cancer, esophageal cancer, malignant melanoma Mouse origin 1/10 PR Not reported 2010 Davis et al. [83]
CEA Colon cancer Mouse origin 1/3 PR Colitis 2011 Parkhurst et al. [84]
NY-ESO-1 Malignant melanoma High-affinity modification 2/11 CR, 3/11 PR, GVHD, Skin erythema, diarrhea, decrease in blood pressure 2011 Robbins et al. [85]
Synovial sarcoma 4/6 PR   
Myeloma 14/20 CR, 4/20 PR 2015 Rapoport et al. [86]
MAGE-A3 Malignant melanoma, myeloma High-affinity modification Not evaluated Cardiogenic shock (death) 2013 Cameron et al. [87]
MAGE-A4 Esophageal cancer Wild type 3/10 long survival Not reported 2015 Kageyamama et al. [88]
WT-1 MDS, AML Wild type 2/8 transient blast loss Not reported 2017 Tawara et al. [89]
Tyrosinase Malignant melanoma Wild type 1/3 PR Vitiligo 2018 Moore et al. [90]
  1. MART melanoma antigen recognized by T cells, CEA carcinoembryonic antigen, MAGE melanoma-associated antigen, CR complete response, PR partial response, MDS myelodysplastic syndrome, AML acute myelogenous leukemia, GVHD graft versus host disease